Abstract
Bullous pemphigoid (BP) is an acquired, subepidermal autoimmune blistering disease. Urticarial and figured erythemas are common prodromal eruptions, and subsequently, large tense blisters arise with a base of normal or erythematous skin. Diagnosis is made by biopsy and direct and indirect immunofluorescence. Topical steroids should be considered first-line treatment in localized or moderate BP, and systemic corticosteroids are rapidly inducing remission in the majority of patients. Other immunosuppressive agents used, among others, are azathioprine, cyclophosphamide, chlorambucil, and mycophenolate mofetil.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsFurther Reading
Bastuji-Garin S, et al. Risk factors for bullous pemphigoid in the elderly: a prospective case–control study. J Invest Dermatol. 2011;131:637–43.
Bouscrarat F, et al. Treatment of bullous pemphigoid with dapsone: retrospective study of thirty six cases. J Am Acad Dermatol. 1996;34:683–7.
Du-Thanh A, et al. Combined treatment with low-dose methotrexate and initial short- term superpotent topical steroids in bullous pemphigoid: an open, multicentre, retrospective study. Br J Dermatol. 2011;165:1337–43.
Engineer L, Ahmed AR. Role of intravenous immunoglobulin in the treatment of bullous pemphigoid. J Am Acad Dermatol. 2001;44:83–8.
Hideyuki U, Akihiko S, et al. What’s new in bullous pemphigoid. J Dermatol. 2010;37:194–204.
Huilgol SC, Black MM. Management of immunobullous diseases. I. Pemphigoid. Clin Exp Dermatol. 1995;20:189–201.
Kolbach DN, et al. Bullous pemphigoid successfully controlled by tetracycline and nicotinamide. Br J Dermatol. 1995;133:88–92.
Orvis AK, et al. Mycophenolate mofetil in dermatology. J Am Acad Dermatol. 2009;60(2):183–99.
Schmidt E, Obe K, Brocker EB, Zillikens D. Serum levels of autoantibodies to BP 180 correlates with disease activity in patients with bullous pemphigoid. Arch Dermatol. 2000;136:174–8.
Tee S, Yosipovitch G, et al. Prevention of glucocorticoid-induced osteoporosis in immunobullous diseases with alendronate: a randomized, double-blind, placebo- controlled study. Arch Dermatol. 2012;148:307–14.
Venning VA, et al. British Association of Dermatologists’ guidelines for the management of bullous pemphigoid 2012. Br J Dermatol. 2012;167:1200–14.
Yancey KB, Egan CA. Pemphigoid. Clinical, histology, immunopathology, and therapeutic considerations. JAMA. 2000;284(3):350–6.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Stavropoulos, P.G., Remoudaki, E. (2015). Bullous Pemphigoid. In: Katsambas, A.D., Lotti, T.M., Dessinioti, C., D’Erme, A.M. (eds) European Handbook of Dermatological Treatments. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-45139-7_11
Download citation
DOI: https://doi.org/10.1007/978-3-662-45139-7_11
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-45138-0
Online ISBN: 978-3-662-45139-7
eBook Packages: MedicineMedicine (R0)